Arrowhead Publishers and Conferences, Washington, D.C.
March 6-7, 2013
CLASSIFICATION - Pathophysiology and molecular based classification (ischemia, axonal injury, etc.) instead of mild, moderate, severe as a more useful classification schema for TBI
- Will help better determine efficacy and clinical endpoints for trials
- PRESENTATIONS: research studies, key opinion leaders on the subject
DIAGNOSTICS - How can they be used to identify and measure pathophysiological processes as targets for therapies and to assess outcomes
- As tools to determine which cases will need what types of post-acute care/therapy
- PRESENTATIONS: case studies on successful use of diagnostics and developmental-stage diagnostics in the clinic
IMAGING - What is the role of imaging in pathophysiology-based classification (e.g., for clinical trials)
- How can it be utilized for patient selection and outcome assessment in clinical trials
- PRESENTATIONS: case studies on successful use of imaging, new research in imaging
OUTCOMES RESEARCH - Coalesce relevant outcomes research to help guide future clinical trials and assessment of therapy in clinical care settings
- Sub-acute recovery
- Neuropsychiatric outcomes
- CTE research
- PRESENTATIONS: cutting edge outcomes research to be presented, key opinion leaders on the subject
|
|
|
Invited Speakers:
|
|
The full speaker list for this conference has not yet been announced. Please check back in the coming weeks for further information. Charles Bernick, MD, Associate Medical Director, Lou Ruvo Center for Brain Health, Cleveland Clinic
Stuart Blincko, Ph.D., Sr. Principal Research Scientist, Abbott Diagnostics
Nicholas Conti, Ph.D., Vice President, Business Development, Quest Diagnostics
Andrew Maas, MD, Ph.D., Professor & Chairman, Department of Neurosurgery,University Hospital Antwerp
Andy Mayer, Ph.D., Associate Professor of Translational Neuroscience, The Mind Research Network, Adjunct Assistant Professor of Neurology and Psychology,University of New Mexico Mark Mintun, MD, Chief Medical Officer, Avid Radiopharmaceuticals (Eli Lilly & Co.) Gregory P. Mueller, Ph.D., Professor, Vice Chair for Research, Uniformed Services University of the Health Sciences Martha Shenton, Ph.D., Professor and Director, Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School
|
|